• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Meta-analysis Assessing the Effect of Sodium-glucose Co-transporter-2 Inhibitors on Left Ventricular Mass in Patients with Type 2 Diabetes Mellitus
Type 2 diabetes mellitus (T2DM) has evolved as a pandemic of the 21st century, while cardiovascular disease (CVD) affects almost one third of patients and represents the cause of death in more than half cases, with coronary artery disease, heart failure (HF) and stroke being the main contributors.1 Hallmark cardiovascular outcome trials published during the last five years have established a novel class of antidiabetics, namely sodium-glucose co-transporter-2 (SGLT-2) inhibitors as a primary treatment option in patients with HF, atherosclerotic cardiovascular disease (ASCVD) or chronic kidney disease (CKD), along with the ...
Source: The American Journal of Cardiology - August 6, 2020 Category: Cardiology Authors: Dimitrios Patoulias, Christodoulos Papadopoulos, Alexandra Katsimardou, Maria-Styliani Kalogirou, Michael Doumas Source Type: research

Development of a new GC –MS/MS method for the determination of metformin in human hair
In this study the authors have developed a GC/MS–MS method for the detection and the quantification of metformin in human hair and have applied it to patients under treatment. Measured concentrations range from 0.3 to 3.8 ng/mg. Me tformin appears to be poorly incorporated into hair, given a daily dose of 1 to 3 g. There is probably a correlation between dose and concentration in dark hair. AbstractDiabetes mellitus is one of the most important public health challenges. Metformin (1,1 ‐dimethylbiguanide) represents the “gold standard” for the treatment of diabetes mellitus type 2. Despite its important role in redu...
Source: Drug Testing and Analysis - June 27, 2020 Category: Drugs & Pharmacology Authors: Nadia Arbouche, Marie ‐Odile Batt, Jean‐Sebastien Raul, Pascal Kintz Tags: SHORT COMMUNICATION Source Type: research

Metformin monotherapy for adults with type 2 diabetes mellitus.
CONCLUSIONS: There is no clear evidence whether metformin monotherapy compared with no intervention, behaviour changing interventions or other glucose-lowering drugs influences patient-important outcomes. PMID: 32501595 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - June 4, 2020 Category: General Medicine Authors: Gnesin F, Thuesen ACB, Kähler LKA, Madsbad S, Hemmingsen B Tags: Cochrane Database Syst Rev Source Type: research

Development of a new GC ‐MS/MS method for the determination of metformin in human hair
AbstractDiabetes mellitus is one of the most important public health challenges. Metformin (1,1 ‐dimethylbiguanide) represents the “gold standard” for the treatment of diabetes mellitus type 2. Despite its important role in reducing mortality and morbidity in the diabetic population, metformin is associated with an increased risk of stroke. To document exposure to a drug, hair is conside red to be the specimen of choice to complement blood and urine, since it provides historical detail of a subject's chronic exposure to drug(s). Measuring hair concentration of metformin can be important for forensic toxicologists inv...
Source: Drug Testing and Analysis - May 28, 2020 Category: Drugs & Pharmacology Authors: Nadia Arbouche, Marie ‐Odile Batt, Jean‐Sebastien Raul, Pascal Kintz Tags: SHORT COMMUNICATION Source Type: research

Budget impact analysis for dapagliflozin in type 2 diabetes in Egypt.
Conclusion: Treating T2DM patients using dapagliflozin instead of conventional medications, maximizes patient's benefits and decreases total costs due to drug cost offsets from fewer cardiovascular and renal events. The adoption of dapagliflozin is a budget-saving treatment option, resulting in substantial population-level health gains due to reduced event rate and cost savings from the perspective of the national healthcare system. PMID: 32364032 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - May 5, 2020 Category: Health Management Tags: J Med Econ Source Type: research

Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
CONCLUSIONS: Metformin compared with placebo or diet and exercise reduced or delayed the risk of T2DM in people at increased risk for the development of T2DM (moderate-quality evidence). However, metformin compared to intensive diet and exercise did not reduce or delay the risk of T2DM (moderate-quality evidence). Likewise, the combination of metformin and intensive diet and exercise compared to intensive diet and exercise only neither showed an advantage or disadvantage regarding the development of T2DM (very low-quality evidence). Data on patient-important outcomes such as mortality, macrovascular and microvascular diabe...
Source: Cochrane Database of Systematic Reviews - December 2, 2019 Category: General Medicine Authors: Madsen KS, Chi Y, Metzendorf MI, Richter B, Hemmingsen B Tags: Cochrane Database Syst Rev Source Type: research

Envisioning the neuroprotective effect of Metformin in experimental epilepsy: A portrait of molecular crosstalk
Publication date: 15 September 2019Source: Life Sciences, Volume 233Author(s): Nandini H S, Yam Nath Paudel, Krishna K LAbstractEpilepsy is a neurological disorder characterized by an enduring predisposition to generate and aggravate epileptic seizures affecting around 1% of global population making it a serious health concern. Despite the recent advances in epilepsy research, no disease-modifying treatment able to terminate epileptogenesis have been reported yet reflecting the complexity in understanding the disease pathogenesis. To overcome the current treatment gap against epilepsy, one effective approach is to explore ...
Source: Life Sciences - August 8, 2019 Category: Biology Source Type: research

Metformin Use and Clinical Outcomes among Patients with Diabetes with or without Heart Failure or Kidney Dysfunction: Observations from the SAVOR-TIMI 53 Trial.
CONCLUSIONS: In a cohort of 12,156 patients with T2DM and high CV risk, metformin use was associated with lower rates of all-cause mortality, including after adjustment for clinical variables and biomarkers, but not lower rates of the composite endpoint of CV death, MI, or ischemic stroke. This association was most apparent in patients without prior HF or moderate to severe CKD. CLINICAL TRIAL REGISTRATION: URL: https://clinicaltrials.gov Unique Identifier: NCT01107886. PMID: 31362530 [PubMed - as supplied by publisher]
Source: Circulation - July 30, 2019 Category: Cardiology Authors: Bergmark BA, Bhatt DL, McGuire DK, Cahn A, Mosenzon O, Steg PG, Im K, Kanevsky E, Gurmu Y, Raz I, Braunwald E, Scirica BM, SAVOR-TIMI 53 Steering Committee and Investigators Tags: Circulation Source Type: research

Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus.
CONCLUSIONS: There is inconclusive evidence whether M+S combination therapy compared with metformin plus another glucose-lowering intervention results in benefit or harm for most patient-important outcomes (mortality, SAEs, macrovascular and microvascular complications) with the exception of hypoglycaemia (more harm for M+S combination). No RCT reported on health-related quality of life. PMID: 30998259 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - April 17, 2019 Category: General Medicine Authors: Madsen KS, Kähler P, Kähler LKA, Madsbad S, Gnesin F, Metzendorf MI, Richter B, Hemmingsen B Tags: Cochrane Database Syst Rev Source Type: research

Neuro-Protective Role of Metformin in Patients with Acute Stroke and Type 2 Diabetes Mellitus via AMPK/Mammalian Target of Rapamycin (mTOR) Signaling Pathway and Oxidative Stress.
CONCLUSIONS Metformin can improve the neurological function and oxidative stress status of acute stroke patients with type 2 diabetes, and its mechanism may be related to the AMPK/mTOR signaling pathway and oxidative stress. PMID: 30905926 [PubMed - in process]
Source: Medical Science Monitor - March 26, 2019 Category: Research Tags: Med Sci Monit Source Type: research

Understanding the cardiovascular risk with non-insulin antidiabetic drugs.
Authors: Athyros VG, Imprialos K, Stavropoulos K, Sahinidis A, Doumas M Abstract INTRODUCTION: Diabetes mellitus is a major public health problem with significant macro- and micro-vascular complications. Achievement of glucose control is associated with substantial reduction of micro-vascular events, while the effects of antidiabetic drugs in macro-vascular complications are less clear. This review summarizes and critically discusses the cardiovascular effects of non-insulin antidiabetic agents. Areas covered: A selective literature search of Pubmed was performed regarding the efficacy and safety of non-insulin ant...
Source: Expert Opinion on Drug Safety - February 28, 2019 Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research

Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus.
CONCLUSIONS: AGI may prevent or delay the development of T2DM in people with IGT. There is no firm evidence that AGI have a beneficial effect on cardiovascular mortality or cardiovascular events. PMID: 30592787 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - December 28, 2018 Category: General Medicine Authors: Moelands SV, Lucassen PL, Akkermans RP, De Grauw WJ, Van de Laar FA Tags: Cochrane Database Syst Rev Source Type: research

Leptin, cardiovascular diseases and type 2 diabetes mellitus.
Abstract Leptin, an adipokine that is implicated in the control of food intake via appetite suppression, may also stimulate oxidative stress, inflammation, thrombosis, arterial stiffness, angiogenesis and atherogenesis. These leptin-induced effects may predispose to the development of cardiovascular diseases. In the present review we discuss the evidence linking leptin levels with the presence, severity and/or prognosis of both coronary artery disease and non-cardiac vascular diseases such as stroke, carotid artery disease, peripheral artery disease (PAD) and abdominal aortic aneurysms (AAA) as well as with chroni...
Source: Acta Pharmacologica Sinica - June 7, 2018 Category: Drugs & Pharmacology Authors: Katsiki N, Mikhailidis DP, Banach M Tags: Acta Pharmacol Sin Source Type: research

Combination of SGLT-2 inhibitors and GLP-1 receptor agonists: potential benefits in surrogate and hard endpoints.
CONCLUSION: The combination of metformin with SGLT2i, GLP-1 RA, and a potent statin, in high CVD risk patients with DM, is expected to substantially reduce CVD mortality and morbidity, improving the quality of life of patients with DM at the same time. Prospective studies are needed to confirm this finding. PMID: 29865997 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - June 3, 2018 Category: Drugs & Pharmacology Authors: Doumas M, Imprialos Κ, Stavropoulos K, Reklou A, Sachinidis A, Athyros VG Tags: Curr Pharm Des Source Type: research

The cardiovascular effect of incretin-based therapies among type 2 diabetes: a systematic review and network meta-analysis.
CONCLUSIONS: Incretin-based therapies show similar cardiovascular risk in comparison with metformin, insulin, thiazolidinediones, alpha-glucosidase inhibitor and sodium-glucose co-transporter 2. GLP-1RA could decrease the risk compared with sulfonylurea or placebo, while DPP-4I appears to have neutral effect on cardiovascular risk. PMID: 29320889 [PubMed - as supplied by publisher]
Source: Expert Opinion on Drug Safety - January 13, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10